93,761 Shares in Kura Oncology, Inc. $KURA Bought by Tidal Investments LLC

Key Points

• Tidal Investments LLC acquired 93,761 shares of Kura Oncology during the second quarter, valued at approximately $1.03 million and representing about 0.11% of the company.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $25.40; Wedbush has the highest target at $38.
• KURA opened at $11.73, while the company reported a quarterly loss of $0.77 per share—better than estimates—and revenue of $20.87 million. Two insiders recently sold shares, though insiders still own 7.6% of the company.

Tidal Investments LLC acquired a new stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 93,761 shares of the company's stock, valued at approximately $1,029,000. Tidal Investments LLC owned approximately 0.11% of Kura Oncology at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. IFP Advisors Inc lifted its holdings in shares of Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company's stock valued at $25,000 after purchasing an additional 1,284 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company's stock worth $43,000 after buying an additional 1,553 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Kura Oncology by 49.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company's stock worth $60,000 after buying an additional 1,888 shares in the last quarter. Pictet Asset Management Holding SA acquired a new stake in Kura Oncology in the 1st quarter valued at approximately $96,000. Finally, E Fund Management Co. Ltd. acquired a new stake in Kura Oncology in the 2nd quarter valued at approximately $132,000.

Wall Street Analyst Weigh In

KURA has been the subject of a number of recent research reports. Citizens Jmp reaffirmed a "market outperform" rating and set a $24.00 price target on shares of Kura Oncology in a research report on Monday, August 24th. Wells Fargo & Company set a $24.00 price objective on shares of Kura Oncology in a report on Thursday, June 4th. Raymond James Financial set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, August 24th. Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a report on Monday, August 24th. Finally, Wedbush raised their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the company an "outperform" rating in a research report on Thursday, August 13th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $25.40.

Kura Oncology Stock Up 0.1%

KURA stock opened at $11.73 on Friday. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -3.48 and a beta of 0.44. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $13.90. The business has a 50 day moving average price of $11.21 and a two-hundred day moving average price of $10.05. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The company had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Analysts anticipate that Kura Oncology, Inc. will post -3.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kura Oncology news, insider Brian Powl sold 4,345 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $11.89, for a total value of $51,662.05. Following the completion of the sale, the insider owned 169,269 shares in the company, valued at $2,012,608.41. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Teresa Bair sold 31,487 shares of Kura Oncology stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total transaction of $397,680.81. Following the completion of the transaction, the insider directly owned 195,444 shares of the company's stock, valued at approximately $2,468,457.72. This trade represents a 13.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.60% of the company's stock.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company's research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura's leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.